Neon shines, but larger trials needed to illuminate full effect
Neon's cancer vaccine makes a decent early showing, but overall survival remain a crucial measure.
Indivior fights off generic challenges but the threat of litigation remains
Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
Venture investing dips again for biopharma
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
Redx sells another asset to keep the lights on
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Medicines Company goes on the hunt for heartening Orion data
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
Probiodrug changes its name but remembers its roots
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
Biopharma set for a big buyout year – on dollar terms at least
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
Big device deals are back in fashion
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
Two more patients bolster Sangamo’s haemophilia A gene therapy
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.